|
COASY |
Coenzyme A synthase |
|
|
|
|
CREBBP |
CREB binding lysine acetyltransferase |
- Regulation of gene expression by Hypoxia-inducible Factor
- BMAL1:CLOCK,NPAS2 activates circadian expression
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- PPARA activates gene expression
- PPARA activates gene expression
- Formation of the beta-catenin:TCF transactivating complex
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- HATs acetylate histones
- Attenuation phase
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- CD209 (DC-SIGN) signaling
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- Activation of the TFAP2 (AP-2) family of transcription factors
- RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- Estrogen-dependent gene expression
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- FOXO-mediated transcription of cell death genes
- Regulation of FOXO transcriptional activity by acetylation
- Regulation of FOXO transcriptional activity by acetylation
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Cytoprotection by HMOX1
- Heme signaling
- Nuclear events mediated by NFE2L2
- NPAS4 regulates expression of target genes
- Formation of paraxial mesoderm
- NFE2L2 regulating inflammation associated genes
- NFE2L2 regulating anti-oxidant/detoxification enzymes
- NFE2L2 regulates pentose phosphate pathway genes
- NFE2L2 regulating tumorigenic genes
- NFE2L2 regulating MDR associated enzymes
- NFE2L2 regulating ER-stress associated genes
- Regulation of NFE2L2 gene expression
- Regulation of NFE2L2 gene expression
- Zygotic genome activation (ZGA)
- Evasion by RSV of host interferon responses
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Transcriptional and post-translational regulation of MITF-M expression and activity
- Transcriptional and post-translational regulation of MITF-M expression and activity
- Regulation of PD-L1(CD274) transcription
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes
- Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters
- The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
- Colforsin
- 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
|
- Rubinstein-Taybi syndrome
|
|
CRH |
corticotropin releasing hormone |
- Class B/2 (Secretin family receptors)
- G alpha (s) signalling events
- MECP2 regulates transcription of neuronal ligands
|
- Corticotropin
- D-Phenylalanine
- 2-aminoisobutyric acid
|
|
|
CRKL |
CRK like proto-oncogene, adaptor protein |
- Frs2-mediated activation
- Frs2-mediated activation
- Downstream signal transduction
- MET activates RAP1 and RAC1
- MET receptor recycling
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Regulation of signaling by CBL
|
|
|
|
CSF1R |
colony stimulating factor 1 receptor |
- Other interleukin signaling
- Transcriptional Regulation by VENTX
- Signaling by CSF1 (M-CSF) in myeloid cells
|
- Imatinib
- Sunitinib
- Linifanib
- 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE
- 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE
- Fostamatinib
- Erdafitinib
- Pexidartinib
|
|
|
CSF2RA |
colony stimulating factor 2 receptor subunit alpha |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes SMDP5
- Defective CSF2RA causes SMDP4
- Interleukin receptor SHC signaling
|
- Sargramostim
- KB002
- Regramostim
- Foreskin fibroblast (neonatal)
- Foreskin keratinocyte (neonatal)
- Clove oil
|
|
|
CSF2RB |
colony stimulating factor 2 receptor subunit beta |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes SMDP5
- Defective CSF2RA causes SMDP4
- Interleukin receptor SHC signaling
|
- Sargramostim
- NPI 32101
- Resatorvid
|
|
|
CSF3R |
colony stimulating factor 3 receptor |
- Other interleukin signaling
- Transcriptional regulation of granulopoiesis
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
|
- Pegfilgrastim
- Filgrastim
- FavId
- Lenograstim
- Lipegfilgrastim
- Eflapegrastim
|
|
|
CSK |
C-terminal Src kinase |
- GAB1 signalosome
- Phosphorylation of CD3 and TCR zeta chains
- Integrin signaling
- Co-inhibition by PD-1
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- RHOH GTPase cycle
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Negative regulation of FLT3
|
- Dasatinib
- Staurosporine
- TG-100801
- Fostamatinib
|
|
|
CSNK2B |
casein kinase 2 beta |
- Synthesis of PC
- WNT mediated activation of DVL
- Condensation of Prometaphase Chromosomes
- Signal transduction by L1
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
- Receptor Mediated Mitophagy
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Regulation of PTEN stability and activity
- KEAP1-NFE2L2 pathway
- Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
- Maturation of hRSV A proteins
- SPOP-mediated proteasomal degradation of PD-L1(CD274)
- Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK
- Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
|
|
|
|
CTLA4 |
cytotoxic T-lymphocyte associated protein 4 |
- Co-stimulation by CD28
- Co-inhibition by CTLA4
- RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
|
- Abatacept
- Ipilimumab
- Tremelimumab
|
- Graves' disease
- Allograft rejection
- Type I diabetes mellitus
- Hashimoto's thyroiditis
|
|
DAPP1 |
dual adaptor of phosphotyrosine and 3-phosphoinositides 1 |
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Inositol 1,3,4,5-Tetrakisphosphate
|
|
|
DLG4 |
discs large MAGUK scaffold protein 4 |
- Signaling by ERBB4
- Trafficking of AMPA receptors
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- NrCAM interactions
- Activation of Ca-permeable Kainate Receptor
- RHO GTPases activate CIT
- RAF/MAP kinase cascade
- LGI-ADAM interactions
- Neurexins and neuroligins
- Neurexins and neuroligins
- Synaptic adhesion-like molecules
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
- Guanidine
- Guanosine-5'-Monophosphate
|
|
|
DOK1 |
docking protein 1 |
- PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
- RET signaling
|
|
|
|
DOK2 |
docking protein 2 |
- Tie2 Signaling
- RET signaling
|
|
|
|
DOK3 |
docking protein 3 |
|
|
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Respiratory syncytial virus (RSV) attachment and entry
- Developmental Lineage of Mammary Gland Myoepithelial Cells
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Poziotinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
- Mobocertinib
- Almonertinib
- Amivantamab
|
- Laryngeal cancer
- Cervical cancer
- Oral cancer
- Gastric cancer
- Choriocarcinoma
- Esophageal cancer
- Glioma
- Bladder cancer
|
|
EPOR |
erythropoietin receptor |
- Signaling by Erythropoietin
- Signaling by Erythropoietin
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
|
- Darbepoetin alfa
- Erythropoietin
- Dibromotyrosine
- Peginesatide
- Methoxy polyethylene glycol-epoetin beta
|
- Congenital polycythemia; Familial erythrocytosis (ECYT)
|
|
ERBB3 |
erb-b2 receptor tyrosine kinase 3 |
|
|
- Type I diabetes mellitus
- Lethal congenital contractural syndrome (LCCS)
|
|
ERBB4 |
erb-b2 receptor tyrosine kinase 4 |
|
- Afatinib
- Fostamatinib
- Brigatinib
- Zanubrutinib
|
|